BlossomHill Therapeutics announced a collaboration with Foundation Medicine to create a companion diagnostic test for the EGFR C797S mutation in non-small cell lung cancer (NSCLC). This test will support the development of BH-30643, a drug designed to overcome resistance to existing EGFR inhibitors like osimertinib. The collaboration leverages ongoing Phase 1/2 trials of BH-30643, which targets various EGFR mutations including the resistance-driving C797S mutation. This partnership aims to improve treatment precision and outcomes for patients with resistant EGFR-mutant NSCLC.
BlossomHill Therapeutics collaboration news offers context for readers. For those tracking health-sector stocks, 66 of 150 US stocks rose and 77 fell on Pluang as of Oct 22, 2026 17:11 WIB. Notable movers include RXRX at USD 3.50 with 0% Sell / 100% Buy order activity, TXG at USD 72.98 with 0% Sell / 100% Buy, and NUWE at USD 0.54 with 0% Sell / 100% Buy and a +3.34% price change.
Lockheed Martin reported strong Q3 2026 results, beating Wall Street estimates with earnings of $7.97 per share and sales of $20.7 billion, up 11% year-over-year. Net earnings rose 14% to $1.8 billion, supported by a record backlog of $292 billion, i...
IBM reported strong Q3 results with revenue of $17.1 billion and adjusted earnings of $2.95 per share, surpassing analyst estimates. Software revenue grew 9%, led by Red Hat and OpenShift, while AI-related consulting work also contributed significant...
Cowen & Co. initiated a 'Buy' rating on CenterPoint Energy before its Q3 earnings report due October 27, 2026. Analysts expect $2.16 billion in revenue, an 8.4% increase year-over-year, and earnings of $0.50 per share, steady from last year. The comp...
Drofa Comms has released the Women Leading the Way Digital Magazine 2026, aiming to highlight women experts in finance on equal terms with men. The digital magazine features insights from 25 industry professionals and covers topics like AI in wealth ...
Tesla reported third-quarter earnings with free cash flow exceeding expectations, but shares fell after hours despite an initial gain. The company lowered its full-year capital expenditure forecast to about $20 billion from over $25 billion, signalin...
